Authors: Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O.
Publication Year: 2008
Citation: Eur Heart J 2008;29(21):2660-8.
This large population study of Danish postmenopausal women found that transdermal estrogen therapy was associated with a significantly lower risk of myocardial infarction than oral unopposed estrogen therapy amongst those using hormone replacement therapy (HRT). The risk of myocardial infarction increased with longer duration of HRT in younger but not older women. A continuous HRT regimen resulted in the greatest risk of myocardial infarction in all age groups, while no increased risk compared to non-HRT users was seen for unopposed estrogen, cyclic estrogen/progestogen HRT, or tibolone. The type of progestogen or dose of estrogen did not appear to affect risk.